secwatch.observer — SEC 8-K summary
======================================

Issuer:     Citius Pharmaceuticals, Inc. (CTXR)
CIK:        0001506251
Form:       8-K
Filed at:   2022-04-13T23:59:59+00:00
Accession:  0001213900-22-019528
Event type: leadership
Sentiment:  positive
Materiality: 0.65
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Citius realigns management: Mazur named CEO; Holubiak becomes Exec. Vice Chairman for commercial launch
--------------------------------------------------------------------------------

- Leonard Mazur appointed CEO and Chairman; Myron Holubiak transitions to Executive Vice Chairman, effective May 1, 2022.
- Holubiak to lead commercial team for upcoming I/ONTAK (CTCL) launch and Mino-Lok Phase 3 completion.
- CFO Jaime Bartushak adds Chief Business Officer role; Michael McGuire joins as VP, Program Leader for Anti-Infectives.
- Holubiak enters amended employment agreement with $450K salary, 50% bonus potential, 18-month initial term.
- Company files Form 8-K; press release dated April 13, 2022, details the changes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1506251/000121390022019528/0001213900-22-019528-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1506251/000121390022019528/ea158351-8k_citius.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-019528

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer